Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).

导出 LinkOut

翻译打印收藏纠错

第一作者： Eisaku,Miyauchi

第一单位： Department of Respiratory Medicine, Tohoku University Hospital, Sendai.

作者： Eisaku,Miyauchi ^[1] ; Akira,Inoue ^[2] ; Kunihiko,Kobayashi ^[3] ; Makoto,Maemondo ^[4] ; Shunichi,Sugawara ^[5] ; Satoshi,Oizumi ^[6] ; Hiroshi,Isobe ^[7] ; Akihiko,Gemma ^[8] ; Yasuo,Saijo ^[9] ; Hirohisa,Yoshizawa ^[10] ; Koichi,Hagiwara ^[11] ; Toshihiro,Nukiwa ^[12] ; North-East Japan Study Group

作者单位： Department of Respiratory Medicine, Tohoku University Hospital, Sendai. ^[1] Department of Respiratory Medicine, Tohoku University Hospital, Sendai akinoue@idac.tohoku.ac.jp. ^[2] Department of Respiratory Medicine, Saitama Medical University Internal Medical Center, Saitama. ^[3] Department of Respiratory Medicine, Miyagi Cancer Center, Miyagi. ^[4] Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai. ^[5] First Department of Medicine, Hokkaido University School of Medicine, Sapporo. ^[6] Department of Medical Oncology, KKR Sapporo Medical Center, Sapporo. ^[7] Department of Pulmonary Medicine and Oncology, Graduate School, Nippon Medical School, Tokyo. ^[8] Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata. ^[9] Bioscience Medical Research Center, Niigata University Medical & Dental Hospital, Niigata. ^[10] Department of Respiratory Medicine, Saitama Medical University, Saitama. ^[11] Department of Respiratory Medicine, South Miyagi Medical Center, Miyagi, Japan. ^[12]

关键词 EGFR gefitinib lung cancer mutation second line